Preclinical Evaluation of a New Series of Albumin-Binding <sup>177</sup>Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics

Preclinical Evaluation of a New Series of Albumin-Binding <sup>177</sup>Lu-Labeled PSMA-Based Low-Molecular-Weight Radiotherapeutics

Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with metastatic castration-resistant prostate cancer. Although results have been encouraging, there is a need to improve the tumor...

Full description

Bibliographic Details
Main Authors: Srikanth Boinapally, Suresh Alati, Zirui Jiang, Yu Yan, Alla Lisok, Rajan Singh, Gabriela Lofland, Il Minn, Robert F. Hobbs, Martin G. Pomper, Sangeeta Ray Banerjee
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Molecules
Subjects:
prostate-specific membrane antigen
radiopharmaceutical therapy
albumin
linker
prostate cancer
Online Access:https://www.mdpi.com/1420-3049/28/16/6158

Similar Items

Similar Items